168 related articles for article (PubMed ID: 2527597)
41. Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide.
Bezwoda WR; Mansoor N; Dansey R
Oncology; 1987; 44(6):345-9. PubMed ID: 3684175
[TBL] [Abstract][Full Text] [Related]
42. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.
Anker GB; Refsum H; Ueland PM; Johannessen DC; Lien EA; Lonning PE
Clin Chem; 1999 Feb; 45(2):252-6. PubMed ID: 9931048
[TBL] [Abstract][Full Text] [Related]
43. Aromatase inhibitors in metastatic breast cancer.
Buzdar AU; Plourde PV; Hortobagyi GN
Semin Oncol; 1996 Aug; 23(4 Suppl 9):28-32. PubMed ID: 8824462
[TBL] [Abstract][Full Text] [Related]
44. Aromatase inhibition for breast cancer treatment.
Lønning PE
Acta Oncol; 1996; 35 Suppl 5():38-43. PubMed ID: 9142963
[TBL] [Abstract][Full Text] [Related]
45. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
46. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
Friedrichs K; Jänicke F
Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
[TBL] [Abstract][Full Text] [Related]
47. Proper sequence of endocrine therapies in advanced breast cancer.
Rose C
Acta Oncol; 1996; 35 Suppl 5():44-9. PubMed ID: 9142964
[TBL] [Abstract][Full Text] [Related]
48. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Rose C
Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
[TBL] [Abstract][Full Text] [Related]
49. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
Häusler A; Schenkel L; Krähenbühl C; Monnet G; Bhatnagar AS
J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
[TBL] [Abstract][Full Text] [Related]
50. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
[TBL] [Abstract][Full Text] [Related]
51. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Lønning PE
Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
[TBL] [Abstract][Full Text] [Related]
53. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
54. [Aromatase inhibitors in adjuvant setting in breast cancer].
Spano JP; Khayat D; Delozier T
Bull Cancer; 2004 Dec; 91 Suppl 4():S239-43. PubMed ID: 15899615
[TBL] [Abstract][Full Text] [Related]
55. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Demers LM
Breast Cancer Res Treat; 1994; 30(1):95-102. PubMed ID: 7949208
[TBL] [Abstract][Full Text] [Related]
56. Letrozole after tamoxifen for breast cancer--what is the price of success?
Bryant J; Wolmark N
N Engl J Med; 2003 Nov; 349(19):1855-7. PubMed ID: 14551339
[No Abstract] [Full Text] [Related]
57. Aromatase inhibitors and their application in breast cancer treatment*.
Brodie AM; Njar VC
Steroids; 2000 Apr; 65(4):171-9. PubMed ID: 10713305
[TBL] [Abstract][Full Text] [Related]
58. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.
Browne LJ; Gude C; Rodriguez H; Steele RE; Bhatnager A
J Med Chem; 1991 Feb; 34(2):725-36. PubMed ID: 1825337
[TBL] [Abstract][Full Text] [Related]
59. Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.
Burstein HJ
N Engl J Med; 2003 Nov; 349(19):1857-9. PubMed ID: 14551340
[No Abstract] [Full Text] [Related]
60. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
